These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 18565684

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The effect of a fibrin-fibronectin/beta-tricalcium phosphate/recombinant human bone morphogenetic protein-2 system on bone formation in rat calvarial defects.
    Hong SJ, Kim CS, Han DK, Cho IH, Jung UW, Choi SH, Kim CK, Cho KS.
    Biomaterials; 2006 Jul; 27(20):3810-6. PubMed ID: 16574220
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Heparin-conjugated fibrin as an injectable system for sustained delivery of bone morphogenetic protein-2.
    Yang HS, La WG, Bhang SH, Jeon JY, Lee JH, Kim BS.
    Tissue Eng Part A; 2010 Apr; 16(4):1225-33. PubMed ID: 19886733
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery).
    Bessa PC, Casal M, Reis RL.
    J Tissue Eng Regen Med; 2008 Apr; 2(2-3):81-96. PubMed ID: 18383454
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Silk fibroin microparticles as carriers for delivery of human recombinant BMPs. Physical characterization and drug release.
    Bessa PC, Balmayor ER, Azevedo HS, Nürnberger S, Casal M, van Griensven M, Reis RL, Redl H.
    J Tissue Eng Regen Med; 2010 Jul; 4(5):349-55. PubMed ID: 20058243
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-term delivery enhances in vivo osteogenic efficacy of bone morphogenetic protein-2 compared to short-term delivery.
    Jeon O, Song SJ, Yang HS, Bhang SH, Kang SW, Sung MA, Lee JH, Kim BS.
    Biochem Biophys Res Commun; 2008 May 02; 369(2):774-80. PubMed ID: 18313401
    [Abstract] [Full Text] [Related]

  • 18. Bone morphogenetic proteins in clinical applications.
    Gautschi OP, Frey SP, Zellweger R.
    ANZ J Surg; 2007 Aug 02; 77(8):626-31. PubMed ID: 17635273
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Selective synthesis of bone morphogenetic proteins-1, -3, -4 and bone sialoprotein may be important for osteoinduction by Saos-2 cells.
    Anderson HC, Reynolds PR, Hsu HH, Missana L, Masuhara K, Moylan PE, Roach HI.
    J Bone Miner Metab; 2002 Aug 02; 20(2):73-82. PubMed ID: 11862528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.